Adverse Effects of Anastrozole in Patients With DCIS
Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).
Brufsky mentions that the two main adverse effects are arthralgia and bone loss. Severe arthralgia occurs in only 10% of patients, and it typically alleviates on its own. There are ways to prevent bone loss as well.
Brufsky believes it would be beneficial to define the subtypes of DCIS that need little to no treatment.
Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
